Surgery, Endoscopy or Medication: The Side-by-Side Chart
Sleeve, bypass, endoscopic sleeve, balloon and GLP-1 medication compared on the published evidence: average weight loss, diabetes remission, durability, typical cost and who each suits best, on one printable chart.
This is a chart of five ways to lose a large share of body weight, set side by side on the things published studies actually measured. Two options have a surgeon remove or reroute part of the stomach: the sleeve and the bypass. One has a gastroenterologist stitch the stomach smaller from the inside: the endoscopic sleeve. One is a balloon. One is a drug: semaglutide or tirzepatide, the GLP-1 medications. Each cell holds a number, the study it came from, and enough context to know how much weight the number can bear.
The rule for reading it is that the units are not interchangeable. Total weight loss is the share of starting body weight that came off. Excess weight loss is the share of the weight above a reference point that came off. The MERIT trial, for example, defined that reference point as a BMI of 25. Excess weight loss is a fraction of a smaller number, so it always looks bigger. A table that mixes the two without labels will flatter whichever option happened to report the bigger-looking unit.
What is not settled is a fairly long list. There are no five-year numbers yet for the endoscopic sleeve or the balloon, and no long-term drug data that rival the 10-year surgical trials. None of these sources gives a typical price for any option. Most drug figures and most surgery figures come from different studies of different people, which reviewers then line up next to each other. The chart does the same thing, and says so.
Weight lost after one and five years
| Option | Weight lost after one year | Weight lost after five years |
|---|---|---|
| Gastric bypass | Not settled for bypass alone in these sources | 22.2 percent in the Oseberg randomized trial; 28.1 percent in a five-year cohort of patients with preoperative dysglycemia |
| Gastric sleeve | Not settled for sleeve alone in these sources | 17.2 percent in Oseberg; 24.0 percent in the dysglycemia cohort; 27.4 percent in the standard arm of a banded versus non-banded sleeve trial; 25 to 30 percent at 2 to 5 years in a review |
| Endoscopic sleeve | 13.6 percent at 52 weeks in the MERIT trial, versus 0.8 percent for controls; 13 to 16 percent at 12 months in a review | Not settled; a review reports results sustained up to 3 years |
| Gastric balloon | About 10 to 15 percent in a 2023 to 2025 narrative review | Not settled; the loss is not sustained after removal |
| GLP-1 drugs | About 10 to 15 percent for GLP-1 agonists in the same review; 22.5 percent for tirzepatide 15 mg in SURMOUNT-1 | 14.9 to 20.9 percent for semaglutide or tirzepatide in a 2026 systematic review, against 25 to 32 percent sustained five-year loss for surgery |
Ten years and beyond
| Option | Horizon and study | Result |
|---|---|---|
| Gastric bypass | 10 years, SLEEVEPASS randomized trial, 85 percent follow-up | 51.9 percent excess weight loss, versus 43.5 percent for sleeve |
| Gastric bypass | 10 to 20 years, Geisinger single center | Total weight loss stabilized at 23 percent |
| Gastric bypass | 7 years, LABS study | 28.4 percent of baseline weight, or 38.2 kg |
| Gastric sleeve | 10 years, weighted mean across studies | 24.4 percent total weight loss |
| One anastomosis bypass | 10 years | 64.1 percent excess weight loss |
| Duodenal switch | 10 years | About 40 percent total weight loss; 76.5 to 78 percent excess BMI loss, with significant nutritional concerns |
| Adjustable band | 7 years, LABS study | 14.9 percent of baseline weight, or 18.8 kg |
| Endoscopic sleeve | Not settled | Not settled |
| Gastric balloon | Not settled | Not settled |
| GLP-1 drugs | Not settled | Not settled |
Diabetes remission
| Option | Finding | Study |
|---|---|---|
| Gastric bypass | 63 percent at 5 years with HbA1c below 6.5 percent; 50 percent with the stricter cutoff of 6.0 percent | Oseberg randomized trial |
| Gastric sleeve | 30 percent at 5 years with HbA1c below 6.5 percent; 20 percent with the 6.0 percent cutoff | Oseberg randomized trial |
| Bypass versus sleeve, earlier | 67 versus 33 percent at 3 years; at 1 year a risk difference of 27 percentage points favoring bypass | Oseberg randomized trial |
| Gastric bypass | 53.3 percent, 8 of 15, at 10 years | DIABETCIR trial |
| Gastric sleeve | 25 percent, 3 of 12, at 10 years | DIABETCIR trial |
| Greater curvature plication | 26.7 percent, 4 of 15, at 10 years | DIABETCIR trial |
| Bypass after weight regain | 75 percent kept remission at 5 years despite regain, versus 34.8 percent after sleeve; odds of recurrence 5.5 times higher after sleeve | Mayo Clinic study |
| Bypass after regaining all lost weight | About 60 percent still in remission | Weight recurrence study |
| One anastomosis bypass, 5 years or more | 80 percent type 2 diabetes resolution across 32 studies and 19,125 patients | Meta-analysis |
| Endoscopic sleeve | 60 percent remission with mild, 45.5 percent with moderate and 0 percent with severe diabetes on the IMS score | IMS score study |
| Gastric balloon | Not settled | None in these sources |
| GLP-1 drugs | 5.8 percent by strict off-medication criteria, up to 18.3 percent by inclusive definitions, among 14,141 initiators followed a mean of 4 years | Observational study |
Who keeps remission after surgery
| Factor | Finding | Study |
|---|---|---|
| Relapse rate | 882 patients, 42.9 percent, restarted diabetes medication after at least 90 medication-free days | Medication re-initiation study |
| Timing | Median time to restarting was 1.04 years | Medication re-initiation study |
| Procedure | Bypass carried lower risk of restarting than sleeve, hazard ratio 0.778 | Medication re-initiation study |
| Diabetes duration | Longer duration raised the risk, hazard ratio 1.219 per standard deviation; shorter duration predicted lasting remission in DIABETCIR | Re-initiation study; DIABETCIR |
| Insulin before surgery | Hazard ratio 1.627 | Medication re-initiation study |
| Baseline HbA1c | Higher HbA1c raised the risk, hazard ratio 1.089 per standard deviation | Medication re-initiation study |
| Age | Not independently associated | Medication re-initiation study |
| First year | Greater first-year weight loss and early rises in GLP-1 secretion predicted lasting remission regardless of technique | DIABETCIR trial |
Durability and regain
| Option | Finding | Study |
|---|---|---|
| Gastric bypass | Mean regain of 3.9 percent of baseline weight between years 3 and 7 | LABS study |
| Gastric bypass | Weight regain affects 10 to 30 percent of patients | Pouch resizing study |
| Gastric bypass | Advantages over sleeve at 1 and 5 years were attenuated at 10 years | DIABETCIR trial |
| Gastric sleeve | Up to half of patients may need conversion surgery | Seven-year conversion study |
| Endoscopic sleeve | 68 percent kept at least 25 percent excess weight loss at 104 weeks | MERIT trial |
| Gastric balloon | Loss is not sustained after device removal | Endobariatrics review |
| GLP-1 drugs | People who stopped were 17.90 percentage points behind those who continued | Discontinuation meta-analysis |
| GLP-1 drugs | After stopping tirzepatide, 9 to 12 percent of body weight returned within 6 months, with about half the net loss retained | SURMOUNT-CN extension |
Cost and who each option suits best
| Option | Typical cost | Where the evidence is strongest |
|---|---|---|
| Gastric bypass | Not public | Type 2 diabetes, where it beat sleeve on remission at 1, 3 and 5 years in Oseberg; also weight-related quality of life, 9.4 points better than sleeve at 3 years |
| Gastric sleeve | Not public | Weight loss of 25 to 30 percent at 2 to 5 years; a network meta-analysis put it at 21.1 percent, statistically level with tirzepatide 10 or 15 mg at 21.3 percent |
| Endoscopic sleeve | Not public | Class 1 and 2 obesity, the MERIT trial population; ranked highest for weight loss among endoscopic therapies at 12 months, ahead of the Spatz3 and Orbera balloons |
| Gastric balloon | Not public | Short-term loss; at removal, all FDA-approved endoscopic therapies beat control |
| GLP-1 drugs | Not public | Trial populations such as SURMOUNT-CN, 210 adults with mean BMI 32.3; remission is likelier with shorter diabetes duration, lower HbA1c, lighter treatment burden and preserved beta-cell function |
After a sleeve that underperformed
| Route | Finding | Study |
|---|---|---|
| Conversion to bypass versus adding a GLP-1 drug | 26.1 versus 13.7 percent total weight loss at 3 years, among 4,901 patients | Multicenter retrospective study |
| SADI versus one anastomosis bypass | SADI produced greater weight loss at 1 year | Revisional meta-analysis |
| One anastomosis bypass as revision | Diabetes remission of 65.16 percent at 1 year, 65.37 percent at 3 years and 78.10 percent at 5 years | Revisional meta-analysis |
| Pouch resizing after bypass | BMI from 39 to 35 at 5 years; comorbidities resolved in 53 percent; 10.4 percent serious complications | High-volume single center |
| Liraglutide plus endoscopic therapy | Comparable to net loss after surgery alone | Systematic review |
How to read this
Read across a row for one study and down a column with caution. The Oseberg trial gives the cleanest bypass versus sleeve comparison because it randomized patients, and its numbers run lower than some cohorts. The 2026 systematic review found surgery ahead of incretin drugs on all five of its primary domains: diabetes remission, weight, major cardiac events and death, NASH resolution, and quality of life. Remission also depends on the cutoff. The same Oseberg patients show 63 percent or 50 percent remission depending on whether the HbA1c line sits at 6.5 or 6.0. Definitions of failure vary too. One review defines weight recurrence as a rise of 25 percent of excess weight loss from the lowest weight. BARI-STEP defined a poor response as under 20 percent loss.
What would change it
The biggest missing cells would fill in with longer endoscopic sleeve follow-up beyond MERIT’s 104 weeks and with randomized drug data running five years and more. The BYPSADIS trial, which compares SADI-S with bypass, will report the share of patients above 30 percent total weight loss at 5 years. Published prices would replace a column that currently says not public. A randomized trial of surgery against tirzepatide or semaglutide in the same patients would settle what the reviews can only approximate.
Sources
- Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
- Laparoscopic Single Anastomosis Duodeno-Ileal Bypass Versus One Anastomosis Gastric Bypass as Revisional Procedures after Sleeve Gastrectomy: Meta-analysis and Systematic Review
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
- Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study
- A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
- Diabetes remission 10 years after bariatric surgery: Extension study of a randomized controlled trial
- Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial
- Gastric Bypass Improves Long-Term Diabetes Remission, Even After Weight Recurrence | ACS
- Continued Diabetes Remission Despite Weight Recurrence: Gastric Bypass Long-Term Metabolic Benefit.
- Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve
- Baseline Diabetes Severity Is the Dominant Predictor of Diabetes Medication Re-Initiation Following Bariatric Surgery
- Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study
- Seven-Year Comparative Outcomes of One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass for Weight Recurrence Regain Post Sleeve Gastrectomy
- Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
- Pouch Resizing for Weight Regain after Roux-En-Y Gastric Bypass: Results from a High-Volume Single Center
- Banded Versus Non-banded Sleeve Gastrectomy: 5-Year Results of a 3-Year Randomized Controlled Trial
- Roux-en-Y gastric bypass results in long-term durable weight loss and diabetes remission: a single center, > 15 year outcomes
- New Study Shows Long-term Effectiveness of Gastric Bypass in Treating Type 2 Diabetes and Obesity - American Society for Metabolic and Bariatric Surgery
- Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
- Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- A randomized open-label multicentre clinical trial comparing single-anastomosis duodenal switch (SADI-S) versus Roux-en-Y gastric bypass for the treatment of severe obesity: BYPSADIS study protocol
- Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study
- Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review
- Comparative effectiveness of balloons, adjustable balloons, and endoscopic sleeve gastroplasty: a network meta-analysis of randomized trials
- Long-Term Outcomes of One Anastomosis Gastric Bypass: A Systematic Review and Meta-Analysis of 5-Year and Beyond
- GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss
- One Anastomosis/Mini-Gastric Bypass (OAGB/MGB) as Revisional Surgery Following Primary Restrictive Bariatric Procedures: a Systematic Review and Meta-Analysis
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
- Frontiers | Endoscopic Management of Weight Recurrence Following Bariatric Surgery
- Scholars@Duke publication: Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial.
- Endobariatrics: well past infancy and maturing rapidly
- Comparison of 5-year glycemic outcomes after sleeve gastrectomy and Roux-en-Y gastric bypass in patients with pre-operative dysglycemia
- Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial
- Tirzepatide Once Weekly for the Treatment of Obesity
- Lilly's SURMOUNT-1 results published in The New ...
- Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis
- 1672-P: Weight Changes after Tirzepatide Cessation in Chinese Adults with Overweight/Obesity—A Real-World Follow-up Study of SURMOUNT-CN Trial
- Lifestyle Modification and Bariatric Surgery in Type 2 Diabetes Remission : Short title: Diabetes Remission Strategies in T2DM
- Advances in Metabolic Bariatric Surgeries and Endoscopic Therapies: A Comprehensive Narrative Review of Diabetes Remission Outcomes
- Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty
Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.